In this episode of the FLASCO OncoPod, host Dr. Edgardo Santos, President of the Florida Society of Clinical Oncology (FLASCO), leads a multidisciplinary discussion on the evolving role of immunohistochemistry (IHC) in precision oncology. Joined by Dr. Lamees Saeed (Tampa General Hospital Cancer Institute), Dr. Jesus Fabregas (Memorial Cancer Institute), Dr. Ana Sandoval (Herbert Wertheim Cancer Institute at Baptist Health South Florida), and Dr. Nathalie McKenzie (AdventHealth Cancer Institute), the panel explores how IHC has evolved from a diagnostic tool into a critical component of biomarker-driven treatment selection.

The panel discusses how expanding biomarker indications are changing when and how testing is performed, from first-line diagnosis through disease progression. Experts explore the growing clinical importance of HER2-low and HER2-ultralow expression in breast cancer, the role of comprehensive biomarker testing in gynecologic malignancies, and how IHC and next-generation sequencing work together to guide personalized treatment strategies in thoracic oncology. The conversation also highlights the importance of standardized pathology reporting, multidisciplinary collaboration, and balancing timely treatment with the need for complete biomarker results to ensure patients receive the most appropriate targeted therapies.

In this episode of the FLASCO OncoPod, host Dr. Edgardo Santos, President of the Florida Society of Clinical Oncology (FLASCO), leads a multidisciplinary discussion on the evolving role of immunohistochemistry (IHC) in precision oncology. Joined by Dr. Lamees Saeed (Tampa General Hospital Cancer Institute), Dr. Jesus Fabregas (Memorial Cancer Institute), Dr. Ana Sandoval (Herbert Wertheim Cancer Institute at Baptist Health South Florida), and Dr. Nathalie McKenzie (AdventHealth Cancer Institute), the panel explores how IHC has evolved from a diagnostic tool into a critical component of biomarker-driven treatment selection.

In part 2, the panel explores why routine biomarker testing is becoming an essential part of cancer care, highlighting how markers such as mismatch repair (MMR), HER2, PD-L1, and Claudin 18.2 are helping clinicians personalize treatment strategies and improve patient outcomes. Through real-world clinical examples, the discussion examines the value of reflex testing, when repeat testing may be appropriate, and how close collaboration between oncologists, pathologists, and multidisciplinary care teams helps ensure patients receive timely, biomarker-driven treatment. The conversation also addresses practical workflow considerations, including pathology communication, turnaround times, and strategies for integrating evolving testing standards into everyday clinical practice.

In this episode of the FLASCO OncoPod, host Dr. Edgardo Santos, President of the Florida Society of Clinical Oncology (FLASCO), leads a multidisciplinary discussion on the evolving role of immunohistochemistry (IHC) in precision oncology. Joined by Dr. Lamees Saeed (Tampa General Hospital Cancer Institute), Dr. Jesus Fabregas (Memorial Cancer Institute), Dr. Ana Sandoval (Herbert Wertheim Cancer Institute at Baptist Health South Florida), and Dr. Nathalie McKenzie (AdventHealth Cancer Institute), the panel explores how IHC has evolved from a diagnostic tool into a critical component of biomarker-driven treatment selection.

The conversation highlights how IHC is shaping clinical decision-making across breast, gastrointestinal, gynecologic, and thoracic cancers, with experts discussing reflex testing, tissue stewardship, workflow between pathology and oncology, and the growing importance of predictive biomarkers such as HER2, PD-L1, mismatch repair (MMR), Claudin 18.2, and hormone receptors. Panelists also share practical insights on when IHC provides the greatest clinical value, how testing protocols have adapted alongside emerging therapies, and why strong communication between clinicians and pathologists is essential for delivering timely, personalized cancer care.

This podcast is being sponsored by Daiichi Sankyo.